Sanofi's diabetes business affected by Q4 falling prices and Covid-19

Sanofi's diabetes business retreated in Q4 of 2020 due to decreased prices and coronavirus.
Photo: FRANCK FIFE/AFP / AFP
Photo: FRANCK FIFE/AFP / AFP
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN

French pharmaceutical company Sanofi has published its fiscal report for Q4 2020, and even though the firm reports a 4.2-percent growth in sales for the business leg over the course of the fourth quarter, the picture is less rosy in view of the diabetes business.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading